A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy

Area of Science:

• Endocrinology
• Gynecology
• Pharmacology

Background:

• Continuous oral estrogen-progestogen therapy is a novel treatment regimen.
• Bleeding disturbances are frequently observed in the initial months of this therapy.

Purpose of the Study:

• To analyze bleeding patterns in post-menopausal women undergoing continuous oral estrogen-progestogen therapy.
• To compare the effects of different doses of norethisterone acetate and megestrol acetate on bleeding.

Main Methods:

• Four groups of 15 post-menopausal women received continuous oral estrogen (2 mg 17 beta-estradiol) with varying progestogen doses for 1 year.
• Progestogens included norethisterone acetate (1 mg or 0.5 mg) and megestrol acetate (5 mg or 2.5 mg).
• Bleeding patterns were analyzed using conventional statistical methods and a stochastic model.

Main Results:

• Eighty percent of bleeding episodes occurred within the first 4 months of therapy.
• Higher doses of both norethisterone acetate and megestrol acetate were associated with significantly less spotting and menstrual-like bleeding compared to lower doses.
• Stochastic analysis confirmed fewer bleeding episodes with high progestogen doses.
• Within high-dose groups, women weighing under 67 kg or amenorrheic for over 5 years experienced less bleeding.

Conclusions:

• Higher progestogen doses in continuous oral estrogen-progestogen therapy effectively reduce bleeding disturbances.
• Dose optimization of progestogens is crucial for managing bleeding patterns in this treatment regimen.
• Patient factors like weight and time since last menstruation may influence bleeding outcomes in high-dose progestogen users.